🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Twenty cycles (that's right 20) of Lutetium-177 PSMA-617 for metastatic castration-resistant cancer!! Check our case report just published in JNM jnm.snmjournals.org/content/early/… Current randomized controlled data demonstrate the safety and efficacy of 6 cycles of

PSMA PET must be used for clinical trial readouts and by regulators. Is PCWG4 coming? Mike Morris will tell us if and how!

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…

... how common is PSMA-negative significant prostate cancer? In the proPSMA study it was 3.3% Hot of the press in JNM: jnm.snmjournals.org/content/early/… Wonderful work from David Chen and team ProsTIC including James Buteau Declan Murphy

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

Lot of content, Great Presentations and discussions during these 2 days ! Thank you all !! Jeremie Calais Thomas Hope PCF Science UCLA UC San Francisco UroToday.com Johannes Czernin

Overview of PSMA RPT trials by Jeremie Calais UCLA UCLA Health UCLA Theranostics

¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q #NuclearMedicine #PETscan Ashwin Singh Parihar, MBBS, MD

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers ProsTIC PCF Science

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

Funding Reductions Threaten the Future of Medical Innovation jnm.snmjournals.org/content/early/…

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

Getting ready for ASCO #ASCO25? ✈️🔬 There’s lots of theranostics … including a dedicated session for prostate cancer. Don’t miss these! 👀

Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track | Jeremie Calais, MD, PhD dissects BULLSEYE (^177Lu‑PSMA‑617 in oHSPC), VIOLET (^161Tb‑PSMA‑I&T in mCRPC), and ENZA‑p (PSMA‑PET TTVol &

The UCLA Nuclear Medicine team is on the ground at #ASCO25 ! Every year, nuclear medicine & theranostics shine brighter on the #ASCO stage. UCLA UCLA Theranostics . #CancerResearch #NuclearMedicine #Theranostics